{
  "catalogId": "882a6b25-874e-4df6-b6e2-38e3951a9d02",
  "name": "ZOLGENSMA",
  "status": "",
  "category": "prescription",
  "registrationValidity": "valid",
  "registrationNumber": "165 75 36125 00",
  "treatmentDescriptions": "Zolgensma is indicated for the treatment of:-\tpatients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1, or-\tpatients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene.",
  "termsOfIssue": "Prescription required",
  "form": "suspension",
  "route": "i.v",
  "site": "",
  "method": "",
  "administrationNotes": "",
  "ingredients": "ONASEMNOGENE ABEPARVOVEC 2 x 10^13 VG /",
  "codes": {
    "atc5": {
      "system": "WHO ATC Classification",
      "code": "M09AX09",
      "name": "ONASEMNOGENE ABEPARVOVEC"
    }
  },
  "contraindications": "",
  "sideEffect": "",
  "warnings": "תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת ",
  "alternativeMedications": [],
  "packaging": [
    {
      "name": "ZOLGENSMA 2*10^13VG / 1ML   VIAL",
      "manufacturer": {
        "name": "נוברטיס פארמה",
        "countryOfOrigin": "IL"
      },
      "strength": {
        "value": 0,
        "unit": ""
      },
      "quantity": {
        "value": 1.0,
        "unit": "units"
      },
      "packagingDescription": "VIAL GLASS TYPE I",
      "shelfLife": "24",
      "storageConditions": "",
      "codes": {
        "moh": "8558",
        "yarpa": "60707",
        "pharmasoft": "26225"
      },
      "manufacturersAdministrationRecommendation": "",
      "pricing": {
        "currency": "ILS",
        "maxWholesalePrice": 7208297.803,
        "retailMargin": 10.0,
        "maxRetailPrice": 7929127.584,
        "maxPriceWithVAT": 9356370.133
      }
    }
  ],
  "metadata": {
    "version": "1.4",
    "lastUpdated": "2025-07-31T10:53:58.611617"
  }
}